1 ONJ appears to be time-dependent with higher risk after
2 ONJ associated with IV bisphosphonate therapy is extreme
3 ONJ occurred posterior to the cuspids (n = 20) mostly in
4 ONJ resolved in 60 patients (62%), resolved and recurred
5 We found
16 ONJ cases among 572,606 cohort members; seven additional
6 We enrolled
191 ONJ cases and 573 controls in 119 dental practices.
7 prospectively for a minimum 3.2 years
after ONJ.
8 The variables predictive of
developing ONJ were dental extraction (P = .009), treatment with pa
9 ered profile in wound-healing markers
during ONJ development.
10 ith recurrent/nonhealing than single-
episode ONJ (84% v 62%; P = .02).
11 ctice-Based Research Network study
estimated ONJ incidence and odds ratios from bisphosphonate exposu
12 xtractions were independent risk factors
for ONJ.
13 ate with physicians to minimize the risk
for ONJ.
14 ons and suggests that the absolute risks
for ONJ from oral bisphosphonates is low.
15 were 15.5 (CI, 6.0-38.7) more likely to
have ONJ than non-exposed patients; however, the sparse numbe
16 ce of dental disease and tooth extraction
in ONJ pathogenesis and help delineate an altered profile i
17 were 62 men; the median age was 61 years
in ONJ patients and 58 years among the rest.
18 The incidence of osteonecrosis of the
jaw (
ONJ) in the population is low, but specifics are unknown
19 Osteonecrosis of the
jaw (
ONJ), a side-effect of bisphosphonate therapy, is charac
20 lation, bone pain, osteonecrosis of the
jaw (
ONJ), atypical fractures, and osteosarcoma.
21 ral fractures, and osteonecrosis of the
jaw (
ONJ), the pathophysiological mechanisms involved are not
22 nal development of osteonecrosis of the
jaw (
ONJ).
23 de a discussion of osteonecrosis of the
jaw (
ONJ).
24 weigh the risk for osteonecrosis of the
jaw (
ONJ).
25 n in patients with osteonecrosis of the
jaw (
ONJ).
26 Osteonecrosis of the
jaws (
ONJ) is a rare but severe complication of antiresorptive
27 onate therapy and osteonecrosis of the
jaws (
ONJ), but neither causality nor specific risks for lesio
28 ients with single, recurrent, and
nonhealing ONJ (P = .2).
29 , 60.7 to 84.2 months), 33 possible cases
of ONJ were reported, all in the zoledronate-treated patien
30 rmed as being consistent with a diagnosis
of ONJ, representing a cumulative incidence of 2.1% (95% CI
31 We report on the frequency
of ONJ and investigate oral health-related quality of life
32 r studies of the pathogenesis and healing
of ONJ are needed.
33 einitiating bisphosphonates after healing
of ONJ is a reasonable option in patients experiencing rela
34 trial is associated with a low incidence
of ONJ but does not seem to adversely affect Oral-QoL.
35 osed patients; however, the sparse number
of ONJ cases limits firm conclusions and suggests that the
36 All potential occurrences
of ONJ were reported as serious adverse events and centrall
37 Higher risk
of ONJ began within 2 years of bisphosphonate initiation an
38 More than a third
of ONJ patients also suffered from long bone fractures (n =
39 Dental treatment
of ONJ should be conservative and provide relief to the pat
40 Dental procedures
preceded ONJ in 46 patients (47%) and were more common in those w
41 Recurrent ONJ followed reinitiation of bisphosphonates in six of 1
42 r infections and four patients had
recurrent ONJ.
43 Committee also discusses measures
regarding ONJ.
44 Incidence of bisphosphonate-
related ONJ in osteoporosis patients is unclear, but several stu
45 Patients with
spontaneous ONJ have a higher risk of nonhealing and recurrence.
46 tal extraction, including 12 patients in
the ONJ group.
47 Median time from MM diagnosis
to ONJ was 8.4 years for the whole group.
48 Oral and intravenous bisphosphonate-
treated ONJ sites had reduced numbers of basal epithelial progen
49 phosphonate use was strongly associated
with ONJ (odds ratios [OR] 299.5 {95%CI 70.0-1282.7} for intr
50 l disease have been strongly associated
with ONJ development.
51 R = 6.6 {1.6-26.6}) remained associated
with ONJ.
52 hosphonate use were strongly associated
with ONJ.
53 osis therapies and many adverse events,
with ONJ an exception.
54 sphosphonate use and other risk factors
with ONJ.
55 examined human tissue from individuals
with ONJ and non-bisphosphonate-treated control individuals t
56 portantly, human biopsies from patients
with ONJ showed similar findings.